NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

NCT06693843

CompletedPhase 2

Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

Conditions: Obesity, Overweight, or Chronic Weight Management

Interventions: Aleniglipron or Placebo, Aleniglipron or Placebo, Aleniglipron or Placebo, Aleniglipron, Aleniglipron

Countries: United States

This study is a randomized, double-blind, placebo-controlled, dose-range finding study of the efficacy, safety, tolerability, PK, and PD of multiple doses of aleniglipron in participants living with overweight or obesity with at least one weight-related comorbidity. Participants will be randomized to aleniglipron or placebo in a ratio of 3:1 within each Cohort receiving multiple-ascending, QD doses of aleniglipron or placebo in titration steps of 4 weeks duration for a total of 36 weeks of treatment. At the end of the study (after completing 36 weeks of treatment), participants will be offered to continue with an open-label extension (OLE) where they will receive aleniglipron for an additional 36 weeks.

Eligibility overview

Sex: ALL

Age: 18 Years to 79 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Signed informed consent
* BMI ≥30 kg/m2 or BMI ≥27.0 kg/m2 and previous/current diagnosis of ≥ 1 obesity related comorbidity

Exclusion Criteria:

* Previous documented diagnosis of diabetes mellitus.
* Self-reported change in body weight \>5% within 3 months before Screening
* Body weight ≤80 kg at Screening
* Have a prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty, if performed \>1 year prior to screening)
Locations (39)
  • Phoenix, Arizona, United States
  • Anaheim, California, United States
  • Los Angeles, California, United States
  • Montclair, California, United States
  • Rancho Cucamonga, California, United States
  • Sacramento, California, United States
  • Spring Valley, California, United States
  • Honolulu, Hawaii, United States
  • Chicago, Illinois, United States
  • Chicago, Illinois, United States
  • Evanston, Illinois, United States
  • Muncie, Indiana, United States
  • Valparaiso, Indiana, United States
  • West Des Moines, Iowa, United States
  • Baton Rouge, Louisiana, United States
  • Richfield, Minnesota, United States
  • City of Saint Peters, Missouri, United States
  • Hazelwood, Missouri, United States
  • Springfield, Missouri, United States
  • Albany, New York, United States
  • Binghamton, New York, United States
  • Brooklyn, New York, United States
  • Rochester, New York, United States
  • Wilmington, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Norman, Oklahoma, United States
  • Medford, Oregon, United States
  • Pittsburgh, Pennsylvania, United States
  • Moncks Corner, South Carolina, United States
  • Chattanooga, Tennessee, United States
  • + 9 more on CT.gov